Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROMISE trial of PSP-guided early meropenem treatment in emergency department patients at risk of sepsis
2025-525006-37-00Phase 3Authorised
- Sponsor
- Hellenic Institute for the Study of Sepsis
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of meropenem and sodium chloride in Infection and sepsis (2 arms), sponsored by Hellenic Institute for the Study of Sepsis. Primary endpoint: 28-day mortality. Planned start Apr 2026; status: authorised.
02
Drugs
meropenemsodium chloride
03
Conditions
Infectionsepsis
Beyond the preview
Go deeper on 2025-525006-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-525006-37-00.